$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx

$bjdx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023067273 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	-$19.62K	$1.227M
YoY Change	-101.37%	-3.98%
% of Gross Profit
Research & Development	$1.397M	$1.676M
YoY Change	1.28%	121.64%
% of Gross Profit
Depreciation & Amortization	$260.0K	$253.2K
YoY Change	517.14%	477.75%
% of Gross Profit
Operating Expenses	$2.341M	$2.904M
YoY Change	-16.69%	42.71%
Operating Profit	-$2.341M	-$2.904M
YoY Change	-16.69%	46.23%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$43.24K	$90.38K
YoY Change	-128.88%	87.04%
Pretax Income	-$2.300M	-$2.813M
YoY Change	-22.29%	45.21%
Income Tax
% Of Pretax Income
Net Earnings	-$2.298M	-$2.813M
YoY Change	-22.36%	45.21%
Net Earnings / Revenue
Basic Earnings Per Share	-$2.08	-$2.75
Diluted Earnings Per Share	-$2.08	-$2.75
COMMON SHARES
Basic Shares Outstanding	1.023M shares	20.46M shares
Diluted Shares Outstanding	1.103M shares	1.023M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.080M	$5.100M
YoY Change	-61.77%	-66.75%
Cash & Equivalents	$5.077M	$5.100M
Short-Term Investments
Other Short-Term Assets	$1.450M	$1.482M
YoY Change	124.15%	42.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.528M	$6.582M
YoY Change	-53.16%	-61.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.322M	$1.464M
YoY Change	6.73%	257.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$29.91K	$31.68K
YoY Change	-10.67%	-9.69%
Total Long-Term Assets	$1.719M	$1.896M
YoY Change	-2.86%	86.44%
TOTAL ASSETS
Total Short-Term Assets	$6.528M	$6.582M
Total Long-Term Assets	$1.719M	$1.896M
Total Assets	$8.247M	$8.478M
YoY Change	-47.49%	-53.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$755.9K	$271.5K
YoY Change	70.63%	38.44%
Accrued Expenses	$2.040M	$1.392M
YoY Change	88.95%	77.72%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.810K
YoY Change	-100.0%
Total Short-Term Liabilities	$2.800M	$1.833M
YoY Change	83.89%	87.08%
LONG-TERM LIABILITIES
Long-Term Debt	$10.00K	$14.10K
YoY Change
Other Long-Term Liabilities	$13.22K	$14.10K
YoY Change	-14.27%	-96.72%
Total Long-Term Liabilities	$13.22K	$14.10K
YoY Change	-14.27%	-96.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.800M	$1.833M
Total Long-Term Liabilities	$13.22K	$14.10K
Total Liabilities	$3.033M	$2.102M
YoY Change	60.11%	49.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.65M	-$22.35M
YoY Change	68.7%	91.83%
Common Stock	$29.86M	$102.00
YoY Change	1481855.48%	-94.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.213M	$6.376M
YoY Change
Total Liabilities & Shareholders Equity	$8.247M	$8.478M
YoY Change	-47.49%	-53.07%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.298M	-$2.813M
YoY Change	-22.36%	45.21%
Depreciation, Depletion And Amortization	$260.0K	$253.2K
YoY Change	517.14%	477.75%
Cash From Operating Activities	-$1.130M	-$1.478M
YoY Change	-10.39%	-10.93%
INVESTING ACTIVITIES
Capital Expenditures	$80.00K	$201.1K
YoY Change	-110.11%	-263.16%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$201.1K
YoY Change	-89.89%	63.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.170M	-2.680K
YoY Change
NET CHANGE
Cash From Operating Activities	-1.130M	-1.478M
Cash From Investing Activities	-80.00K	-201.1K
Cash From Financing Activities	1.170M	-2.680K
Net Change In Cash	-40.00K	-1.682M
YoY Change	-98.05%	-5.66%
FREE CASH FLOW
Cash From Operating Activities	-$1.130M	-$1.478M
Capital Expenditures	$80.00K	$201.1K
Free Cash Flow	-$1.210M	-$1.679M
YoY Change	157.68%	9.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41031
	dei	Entity Registrant Name EntityRegistrantName	Bluejay Diagnostics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3552922
	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Massachusetts Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 203
	dei	Entity Address City Or Town EntityAddressCityOrTown	Acton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	01720
	dei	City Area Code CityAreaCode	(844)
	dei	Local Phone Number LocalPhoneNumber	327-7078
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	BJDX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1023345	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5100407	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10114990	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1481512	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1673480	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	6581919	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11788470	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1464125	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1232070	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400609	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465514	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31675	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35211	usd
CY2023Q2	us-gaap	Assets Assets	8478328	usd
CY2022Q4	us-gaap	Assets Assets	13521265	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	271488	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	635818	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	168713	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	168706	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1392378	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	835730	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1832579	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1640254	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	255306	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	323915	usd
CY2023Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14104	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15823	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2101989	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1979992	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7500000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	7500000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1023345	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1023345	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1010764	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1010764	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	102	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	101	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28726487	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28538274	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-22350250	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-16997102	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6376339	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11541273	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8478328	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13521265	usd
CY2022Q2	us-gaap	Revenues Revenues	249040	usd
	us-gaap	Revenues Revenues	249040	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	200129	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	200129	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	48911	usd
	us-gaap	Gross Profit GrossProfit	48911	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1676256	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	756283	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3030805	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1451040	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1073103	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1196996	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2250080	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2516815	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	154329	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	81357	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	302375	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	135042	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2903688	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2034636	usd
	us-gaap	Operating Expenses OperatingExpenses	5583260	usd
	us-gaap	Operating Expenses OperatingExpenses	4102897	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2903688	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1985725	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5583260	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4053986	usd
CY2023Q2	us-gaap	Other Income OtherIncome	90383	usd
CY2022Q2	us-gaap	Other Income OtherIncome	48323	usd
	us-gaap	Other Income OtherIncome	230112	usd
	us-gaap	Other Income OtherIncome	103181	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	90383	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48323	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	230112	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	103181	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2813305	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1937402	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5353148	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3950805	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.75
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1023052	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1007115	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1020865	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1007115	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11541273	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	54730	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	107234	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2539843	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9163395	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	27702	usd
CY2023Q2	bjdx	Stock Issued During Period Restricted Stock Units Tax Value StockIssuedDuringPeriodRestrictedStockUnitsTaxValue	-1453	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2813305	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6376339	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	20381709	usd
CY2022Q1	bjdx	Cumulative Effect Period Of Adoption Adjusted Balance CumulativeEffectPeriodOfAdoptionAdjustedBalance	-5368	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	126086	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2013403	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	18489024	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	106114	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1937402	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16657736	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5353148	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3950805	usd
	us-gaap	Depreciation Depreciation	373192	usd
	us-gaap	Depreciation Depreciation	83792	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	247293	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	232200	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	80655	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	66972	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1787	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	671250	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-191968	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-575563	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3536	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	14056	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-429590	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-99670	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	2000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	472980	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	242937	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4411327	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3536317	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	541774	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	169599	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-541774	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-169599	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	59079	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2403	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-61482	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5014583	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3705916	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10114990	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19047778	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5100407	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15341862	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	65260	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) is a medical diagnostics company developing rapid tests using whole blood on our Symphony technology platform (“Symphony”) to improve patient outcomes in critical care settings. The Company’s Symphony platform is a combination of Bluejay’s intellectual property (“IP”) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges that if cleared, authorized, or approved by the U.S. Food and Drug Administration (the “FDA”), can provide a solution to a significant market need in the United States. Clinical trials indicate the Symphony device produces laboratory-quality results in less than 20 minutes in intensive care units and emergency rooms, where rapid and reliable results are required.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bluejay’s first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. IL-6 is a clinically established inflammatory biomarker, considered a ‘first-responder,’ for assessment of severity of infection and inflammation across many disease indications, including sepsis. A current challenge of healthcare professionals is the excessive time and cost associated determining a patient’s level of severity at triage and the Symphony IL-6 test has the ability to consistently monitor this critical care biomarker with rapid results.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the future, Bluejay plans to develop additional tests for Symphony including two cardiac biomarkers (hsTNT and NT pro-BNP), as well as other tests using the Symphony platform. The Company does not yet have regulatory clearance for its Symphony products, and its Symphony products will need to receive regulatory authorization from the FDA in order to be marketed as a diagnostic product in the United States.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bluejay’s operations to date have been funded primarily through the proceeds of the Company’s initial public offering (the “IPO”) in November 2021 (the “IPO Date”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 4, 2021, the Company formed Bluejay Spinco, LLC, a wholly owned subsidiary of the Company, for potential further development of the Company’s ALLEREYE diagnostic test. ALLEREYE is a point-of-care device offering healthcare providers a solution for diagnosing Allergic Conjunctivitis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA Regulatory Strategy</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company’s current regulatory strategy is designed to support commercialization of Symphony in the United States pending marketing authorization from the FDA. The Company has shifted its focus away from COVID-19 patients due to a significant decline in the number of COVID-19 related hospitalizations. Based on this revised strategy, the Company plans to conduct a clinical study to support an FDA regulatory submission with an initial indication for risk stratification of hospitalized sepsis patients. The Company submitted a pre-submission application to the FDA presenting the new study design in May 2023 and participated in a pre-submission meeting on August 11, 2023. At the meeting, the FDA provided feedback on the new study design, determined that the submission of a 510(k) is the appropriate premarket submission pathway, and requested that certain data be provided in the 510(k). Based on this feedback, the Company intends to proceed as planned while taking into account the FDA’s feedback. The Company believes that it will maintain the previously disclosed Symphony IL-6 regulatory submission timeline of the first half of 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company has targeted large, well-known medical and academic institutions for its study, which the Company believes will help support initial commercialization and market penetration. The Company believes that this clinical trial expansion could also support additional indications, but that any such expansion also could delay obtaining marketing authorization for the product. Based on the pre-submission meeting with the FDA, the focus of the clinical trial will be the risk stratification of hospitalized sepsis patients.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span>The Company maintains contracts with Toray Industries, Inc (“Toray”) to manufacture our cartridges and Sanyoseiko Co. Ltd (“Sanyoseiko”) to manufacture both our device and cartridges</span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted above, <span>Bluejay is reliant upon Toray and Sanyoseiko to provide cartridges in sufficient quantity and quality to complete our clinical trials, and our clinical trials could be delayed if the Company encountered any material supply interruptions while the clinical trials are being conducted. In addition, </span>there can be no assurance that we will be able to obtain necessary regulatory authorization for the manufacturing or marketing of the <span>Symphony in the United States or elsewhere</span>. There also can be no assurance that we will successfully complete any clinical evaluations necessary to receive regulatory approvals, or that the clinical trial will demonstrate sufficient safety and efficacy of the Symphony. The failure to adequately demonstrate the clinical performance of the Symphony device could delay or prevent regulatory approval of the device, which could prevent or result in delays to market launch and could materially harm our business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the FDA regulatory strategy risks and uncertainties, the Company is subject to a number of risks similar to other companies in its industry, including rapid technological change, competition from larger biotechnology companies and dependence on key personnel. The Company is also impacted by inflationary pressures and global supply chain disruptions currently impacting many companies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">On October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). On April 25, 2023, at the Company’s request, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time for the Company to regain compliance with the Minimum Bid Requirement until October 23, 2023. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten consecutive business days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">On July 24, 2023, the Company executed a reverse stock split of its shares of common stock at a ratio of 1-for-20 (the “Reverse Stock Split”), with a corresponding reduction in the number of authorized outstanding number of shares of common stock from 100,000,000 to 7,500,000. The Reverse Stock Split became effective on July 24, 2023, when the Company’s common stock opened for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol, “BJDX.” At such time, the Company’s common stock also commenced trading with a new CUSIP number, 095633301.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">On August 8, 2023, the Company received a letter from the Listing Qualifications Department of Nasdaq notifying the Company that, based on the closing bid price of the Company’s common stock having been at least $1.00 per share for the required period, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum bid price deficiency matter previously disclosed by the Company on October 25, 2022 is now closed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; "> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; ">All of the Company’s historical share and per share information related to issued and outstanding common stock and outstanding options and warrants exercisable for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-20 reverse stock split.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Consolidated Financial Statements for the interim periods ended June 30, 2023 and 2022 were prepared under the assumption that the Company will continue as a going concern, which contemplates that the Company will be able to realize assets and discharge liabilities in the normal course of business. However, the Company has incurred net losses since its inception, and has negative cash flows from operations and will need additional funding to complete planned development efforts. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had cash and cash equivalents of $5.1 million as of June 30, 2023. It continues to develop the Symphony device and its first test for the measurement of IL-6. It remains committed to obtaining FDA clearance and will conduct clinical trials to obtain sufficient data to support its FDA submission, while also continuing to build its manufacturing operations with its contract manufacturing organizations. Current cash resources and expected operating expenses are considered in determining its liquidity requirement; as well as $1.8 million of current liabilities on its balance sheet as of June 30, 2023 and commitments of approximately $1.9 million as of June 30, 2023 (see Notes 8 and 9). The Company estimates cash resources will be sufficient to fund its operations into the fourth quarter of 2023. The Company will need additional capital to fund its planned operations for the next 12 months.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects that it will seek to raise such additional capital through public or private equity offerings, grant financing and support from governmental agencies, convertible debt, collaborations, strategic alliances and distribution arrangements. Additional funds may not be available when it needs them on terms that are acceptable to them, or at all. If adequate funds are not available, it may be required to delay its FDA regulatory strategy, and to delay or reduce the scope of its research or development programs, its commercialization efforts or its manufacturing commitments and capacity. In addition, if it raises additional funds through collaborations, strategic alliances or distribution arrangements with third parties, it may have to relinquish valuable rights to its technologies or future revenue streams.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in conformity with generally accepted accounting principles in the United States (“US GAAP”) consistent with those applied in, and should be read in conjunction with, the Company’s audited financial statements and related footnotes for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K. The unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023 and December 31, 2022, its results of operations and cash flows for the three and six months ended June 30, 2023 and 2022, in accordance with US GAAP. The unaudited condensed consolidated financial statements do not include all of the information and footnotes required by US GAAP for complete financial statements, as allowed by the relevant U.S. Securities and Exchange Commission (“SEC”) rules and regulations; however, the Company believes that its disclosures are adequate to ensure that the information presented is not misleading. The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25pt; text-align: justify">The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other interim period within this fiscal year.</p>
CY2023Q2	bjdx	Common Stock Closing Price CommonStockClosingPrice	1
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
	bjdx	Unrestricted Cash And Cash Equivalents UnrestrictedCashAndCashEquivalents	5100000	usd
CY2023Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	1800000	usd
CY2023Q2	us-gaap	Other Commitment OtherCommitment	1900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in these condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. The Company believes judgment is involved in accounting for the fair value-based measurement of stock-based compensation, accruals, and warrants. The Company evaluates its estimates and assumptions as facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ from these estimates and assumptions, and those differences could be material to the condensed consolidated financial statements.</p>
	bjdx	Option To Purchase Common Stock OptionToPurchaseCommonStock	35858	usd
	bjdx	Option To Purchase Common Stock OptionToPurchaseCommonStock	40290	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	9875	usd
CY2023Q2	bjdx	Class A Warrants For Common Stockin Shares ClassAWarrantsForCommonStockinShares	40594	usd
CY2022Q2	bjdx	Class A Warrants For Common Stockin Shares ClassAWarrantsForCommonStockinShares	40594	usd
CY2020Q4	bjdx	Royalty Percentage RoyaltyPercentage	0.15	pure
CY2020Q4	bjdx	Sale Term SaleTerm	P5Y
	bjdx	Class B Warrant Rights Description ClassBWarrantRightsDescription	Holders of Class B Warrants may also exercise such warrants on a “cashless” basis after the earlier of (i) 10 trading days from closing date of the offering or (ii) the time when $10.0 million of volume is traded in the Company’s common stock, if the volume weighted average price of the Company’s common stock on any trading day on or after the closing date of the offering fails to exceed the exercise price of the Class B Warrant (subject to adjustment as described in the warrant agreement).
	bjdx	Cash Received From Related Party CashReceivedFromRelatedParty	40886	usd
CY2022Q4	bjdx	Related Partys Transaction Due From To Related Party RelatedPartysTransactionDueFromToRelatedParty	19731	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	25.8
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	25609	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.8
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	19484	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	9.45
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	750	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	25.8
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	8375	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	11.84
CY2023Q1	bjdx	Restricted Stock Units Bonus Grant RestrictedStockUnitsBonusGrant	18734	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35992	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.25
	bjdx	Weighted Average Remaining Contractual Life In Years Outstanding At Begining Balance WeightedAverageRemainingContractualLifeInYearsOutstandingAtBeginingBalance	P6Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	20578	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.6
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	1133	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	64
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	35858	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.67
	bjdx	Weighted Average Remaining Contractual Life In Years Outstanding At Ending Balance WeightedAverageRemainingContractualLifeInYearsOutstandingAtEndingBalance	P7Y4M24D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	9531	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	28222	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	37.22
	bjdx	Weighted Average Remaining Contractual Life In Years Exercisable WeightedAverageRemainingContractualLifeInYearsExercisable	P7Y1M6D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	9531	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.8
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.33
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	400609	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465514	usd
CY2023Q2	bjdx	Financeleaseassetnet financeleaseassetnet	21067	usd
CY2022Q4	bjdx	Financeleaseassetnet financeleaseassetnet	21067	usd
CY2023Q2	bjdx	Total Lease Rightof Use Assets TotalLeaseRightofUseAssets	421676	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0363	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0878	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27703	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106114	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	247292	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	232200	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	56881	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P0Y10M24D
CY2021	bjdx	Employees Cost Plus Percentage EmployeesCostPlusPercentage	0.10	pure
	bjdx	Schedule Of Amounts Earned And Due ScheduleOfAmountsEarnedAndDue	The table below summarizes the amounts earned and due from NanoHybrids<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Six Months Ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Income from NanoHybrids included in Other Income</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,975</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">35,040</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">136,773</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,926</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash receipts from NanoHybrids</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">136,773</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">18,347</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">156,504</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">40,886</td><td style="text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, <br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Amounts receivable from NanoHybrids included in Prepaids and Other Current Assets</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">19,731</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2023Q2	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	40975	usd
CY2022Q2	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	35040	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	136773	usd
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	75926	usd
CY2023Q2	bjdx	Cash Received From Related Party CashReceivedFromRelatedParty	136773	usd
CY2022Q2	bjdx	Cash Received From Related Party CashReceivedFromRelatedParty	18347	usd
	bjdx	Cash Received From Related Party CashReceivedFromRelatedParty	156504	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2433024	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1828476	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	968899	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	596406	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1464125	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1232070	usd
	us-gaap	Depreciation Nonproduction DepreciationNonproduction	247000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M18D
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2023Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07	pure
	us-gaap	Operating Lease Payments OperatingLeasePayments	84352	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	71421	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2403	usd
CY2022Q4	bjdx	Total Lease Rightof Use Assets TotalLeaseRightofUseAssets	486581	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	168713	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	168706	usd
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4807	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4807	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	255306	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	323915	usd
CY2023Q2	bjdx	Noncurrent Finance Lease Liabilities Included In Other Noncurrent Liabilities NoncurrentFinanceLeaseLiabilitiesIncludedInOtherNoncurrentLiabilities	14103	usd
CY2022Q4	bjdx	Noncurrent Finance Lease Liabilities Included In Other Noncurrent Liabilities NoncurrentFinanceLeaseLiabilitiesIncludedInOtherNoncurrentLiabilities	15823	usd
	bjdx	Total Lease Liabilities TotalLeaseLiabilities	442928	usd
CY2022	bjdx	Total Lease Liabilities TotalLeaseLiabilities	513251	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	84354	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	162991	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	100000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	100000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	25000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	472345	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	48326	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	424019	usd
	us-gaap	Manufacturing Costs ManufacturingCosts	383000	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	416000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.15	pure
	bjdx	Underlying Patent Term UnderlyingPatentTerm	P5Y
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	352436	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	751979	usd
CY2023Q2	bjdx	Vendor Prepayments VendorPrepayments	-950607	usd
CY2022Q4	bjdx	Vendor Prepayments VendorPrepayments	-681218	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	178469	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	240283	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1481512	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1673480	usd
CY2023Q2	bjdx	Accrued Personnel Costs AccruedPersonnelCosts	568350	usd
CY2022Q4	bjdx	Accrued Personnel Costs AccruedPersonnelCosts	533577	usd
CY2023Q2	bjdx	Accrued Good Receipts AccruedGoodReceipts	100249	usd
CY2022Q4	bjdx	Accrued Good Receipts AccruedGoodReceipts	10077	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	723779	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	292076	usd
CY2023Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1392378	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	835730	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Gross Profit GrossProfit		usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.75
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.24
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007115	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1007115	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1020865	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1023052	shares
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories		usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	bjdx	Weighted Average Remaining Contractual Life In Years Cancelled And Forfeited WeightedAverageRemainingContractualLifeInYearsCancelledAndForfeited
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2022Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability		usd
CY2023Q2	bjdx	Lessor Operating Lease Paymentstobe Received Thereafter LessorOperatingLeasePaymentstobeReceivedThereafter		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001704287

Files In Submission

Name	View Source	Status
bjdx-20230630_cal.xml	Edgar Link	unprocessable
bjdx-20230630_lab.xml	Edgar Link	unprocessable
0001213900-23-067273-index-headers.html	Edgar Link	pending
0001213900-23-067273-index.html	Edgar Link	pending
0001213900-23-067273.txt	Edgar Link	pending
0001213900-23-067273-xbrl.zip	Edgar Link	pending
bjdx-20230630.xsd	Edgar Link	pending
f10q0623ex31-1_bluejay.htm	Edgar Link	pending
f10q0623ex31-2_bluejay.htm	Edgar Link	pending
f10q0623ex32-1_bluejay.htm	Edgar Link	pending
f10q0623ex32-2_bluejay.htm	Edgar Link	pending
f10q0623_bluejay.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
bjdx-20230630_pre.xml	Edgar Link	unprocessable
bjdx-20230630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0623_bluejay_htm.xml	Edgar Link	completed
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx

2023 Q3 Form 10-Q Financial Statement

#000121390023067273 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BJDX Bluejay Diagnostics, Inc. Stock $bjdx

2023 Q3 Form 10-Q Financial Statement

#000121390023067273 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BJDX
Bluejay Diagnostics, Inc. Stock $bjdx